Outcomes of patients treated with drugcoated balloons for de novo large coronary vessels  

作　　者：QIU Jing 邱竞(Dept Cardiol,1st Affili Hosp Zhengzhou Univ)

机构地区：[1]Dept Cardiol,1st Affili Hosp Zhengzhou Univ

出　　处：《China Medical Abstracts(Internal Medicine)》2019年第3期156-157,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate the efficacy and safety of drug-coated balloons(DCB)for de novo large coronary vessels.Methods One hundred and two patients were retrospectively enrolled in this study,there were 104 lesions with the reference lumen diameter of target vessel more than 2.8 mm and patients were treated with DCB in de novo lesions during May 2015 and July 2017 in our center.Coronary artery angiography and quantitative coronary angiography were performed in 82(80.4%)patients at follow up period((8.1±1.7)months post procedure).The endpoints were late lumen loss(LLL)atfollow up,and major adverse cardiac events(MACE)including cardiac death,myocardial infarction(MI),target lesion revascularization(TLR)and stent or targetlesion thrombosis at 12 months post procedure.ResultsNinety-eight lesions were treated with DCB only,6(5.9%)bailout drug-eluting stent(DES)were usedbecause of severe coronary dissection,2 patients(2.0%)received revascularization driven by acute ischemic eventsduring hospitalization.Cutting balloons and NSE balloonswere used in 65.4%(68/104)and 26.0%(27/104)lesions.The lesion length was(12.57±3.58)mm andthe DCB length was(19.87±4.55)mm.The late lumenloss was(0.01±0.52)mm during angiographic followup.The TLR rate and overall MACE rate was 3.9%(4/102)and 3.9%(4/102)and there was no death,MI andtarget lesion thrombosis at 12 months follow up.ConclusionDCB treatment for de novo large coronaiy vessels iseffective and safe.

关 键 词：BALLOON PATIENTS CORONARY 

分 类 号：R54[医药卫生—心血管疾病]